Page last updated: 2024-11-09

rhodotorulic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhodotorulic acid: RN given refers to (1S-cis)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rhodotorulic acid : A member of the class of 2,5-diketopiperazines obtained by cyclodimerisation of N(5)-acetyl-N(5)-hydroxy-L-ornithine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID688571
CHEMBL ID114350
CHEBI ID84731
MeSH IDM0044328

Synonyms (17)

Synonym
acetohydroxamic acid, n,n'-((3,6-dioxo-2,5-piperazinediyl)bis(trimethylene)di-, l-
(2s-cis)-n,n'-((3,6-dioxo-2,5-piperazinediyl)di-3,1-propanediyl)bis(n-hydroxyacetamide)
einecs 242-681-9
nsc 143096
acetamide, n,n'-((3,6-dioxo-2,5-piperazinediyl)di-3,1-propanediyl)bis(n-hydroxy-, (2s-cis)-
acetamide, n,n'-(((2s,5s)-3,6-dioxo-2,5-piperazinediyl)di-3,1-propanediyl)bis(n-hydroxy-
brn 0965705
rhodotorulic acid
18928-00-2
chebi:84731 ,
CHEMBL114350
61f3vbq4g5 ,
unii-61f3vbq4g5
5-25-17-00340 (beilstein handbook reference)
n,n'-{[(2s,5s)-3,6-dioxopiperazine-2,5-diyl]dipropane-3,1-diyl}bis(n-hydroxyacetamide)
n,n'-(3,3'-((2s,5s)-3,6-dioxopiperazine-2,5-diyl)bis(propane-3,1-diyl))bis(n-hydroxyacetamide)
DTXSID20940439
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
siderophoreAny of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
2,5-diketopiperazinesAny piperazinone that has a piperazine-2,5-dione skeleton.
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
L-ornithine derivativeAn ornithine derivative resulting from reaction of L-ornithine at the amino group, the carboxy group or the side-chain amino group, or from the replacement of any hydrogen of L-ornithine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID69465The ability of the artificial siderophores to support the growth of Escherichia coli strain RW 193 was evaluated at the concentration of 50 uM.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Artificial siderophores. 2. Syntheses of trihydroxamate analogues of rhodotorulic acid and their biological iron transport capabilities in Escherichia coli.
AID69459The ability of the artificial siderophores to support the growth of Escherichia coli strain BN 3300 was evaluated at the concentration of 50 uM; No growth around the disc1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Artificial siderophores. 2. Syntheses of trihydroxamate analogues of rhodotorulic acid and their biological iron transport capabilities in Escherichia coli.
AID69462The ability of the artificial siderophores to support the growth of Escherichia coli strain BN 3306 was evaluated at the concentration of 50 uM; No growth around the disc1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Artificial siderophores. 2. Syntheses of trihydroxamate analogues of rhodotorulic acid and their biological iron transport capabilities in Escherichia coli.
AID69455The ability of the artificial siderophores to support the growth of Escherichia coli strain AN 193 was evaluated at the concentration of 50 uM.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Artificial siderophores. 2. Syntheses of trihydroxamate analogues of rhodotorulic acid and their biological iron transport capabilities in Escherichia coli.
AID69582The ability of the artificial siderophores to support the growth of Escherichia coli strain RWB7 was evaluated at the concentration of 50 uM; No growth around the disc1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Artificial siderophores. 2. Syntheses of trihydroxamate analogues of rhodotorulic acid and their biological iron transport capabilities in Escherichia coli.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (56.76)18.7374
1990's3 (8.11)18.2507
2000's9 (24.32)29.6817
2010's4 (10.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.27 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (10.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (89.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]